🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "huge turning point" in the effort against superbug strains of the pathogen, according to researchers.

An International Health Concern

The sexually transmitted infection are escalating worldwide, with figures suggesting over 82 million instances per year. Especially elevated rates are seen in the African continent and countries within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. Within England, cases have reached a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely development in the context of growing infection rates, increasing antimicrobial resistance and the extremely scarce therapeutic options currently available.”

Health officials are particularly alarmed about the rise in drug-resistant strains. The global health body has listed it as a "high-priority threat". Recent surveillance revealed that resistance to primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Gain Approval

One new antibiotic, marketed under the name a brand name, was approved by the US FDA in December for use against gonorrhoea. This disease can lead to serious health problems, including infertility. Experts hope that targeted use of this new drug will help hinder the development of resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, gained clearance in concurrent days. This medication, which is also used to treat urinary tract infections, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin stemmed from a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to see it through.

“This milestone signifies a huge turning point in the therapy of highly resistant gonorrhoea, which previously has been outpacing medical innovation.”

Clinical Trial Outcomes and Worldwide Availability

Based on data released by a major medical journal, the new drug successfully treated more than 90% of uncomplicated infections. This places it at an comparable level with the current standard treatment, which uses an injection and a pill. The study included over 900 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, GARDP has the ability to make available and distribute the drug in many low-income and middle-income countries.

Clinicians treating patients have shared optimism. Access to a one-pill regimen like this is hailed as a "game-changer" for gonorrhoea control. This is viewed as crucial to alleviate the strain of the disease for patients and to prevent the spread of untreatable gonorrhoea around the world.